These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9834819)

  • 21. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The emerging world role of irinotecan in lung cancer.
    Langer CJ
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):15-21. PubMed ID: 11497227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials.
    Hotta K; Fujiwara Y; Kiura K; Takigawa N; Tabata M; Ueoka H; Tanimoto M
    J Thorac Oncol; 2007 May; 2(5):402-7. PubMed ID: 17473655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
    Chen YM; Shih JF; Lee CS; Chen MC; Lin WC; Tsai CM; Perng RP
    Lung Cancer; 2003 Feb; 39(2):209-14. PubMed ID: 12581575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer.
    Krug LM; Miller VA
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):24-6; discussion 41-2. PubMed ID: 10585005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study.
    Pérol M; Léna H; Thomas P; Robinet G; Fournel P; Coste E; Belleguic C; Le Caer H; Blanchon F; Vergnenègre A; Vernejoux JM; Schuller-Lebeau MP; Pham E
    Ann Oncol; 2002 May; 13(5):742-7. PubMed ID: 12075743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
    Masuda N
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
    Devore R; Johnson D; Crawford J; Dimery I; Eckardt J; Eckhardt SG
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):79-83. PubMed ID: 9726097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer.
    Masters GA; Mauer AM; Hoffman PC; Wyka D; Samuels BL; Krauss SA; Watson S; Golomb H; Vokes EE
    Ann Oncol; 1998 Jun; 9(6):677-80. PubMed ID: 9681085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer.
    Belani CP;
    Semin Oncol; 2002 Jun; 29(3 Suppl 12):4-9. PubMed ID: 12170445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
    Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
    Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
    Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F
    Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
    Khuri FR
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):53-62. PubMed ID: 12108898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials.
    Dowlati A; Crosby L; Remick SC; Makkar V; Levitan N
    Lung Cancer; 2001 May; 32(2):155-62. PubMed ID: 11325486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eastern Cooperative Oncology Group experience with chemotherapy in advanced non-small cell lung cancer.
    Bonomi P
    Chest; 1998 Jan; 113(1 Suppl):13S-16S. PubMed ID: 9438684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.
    Pectasides D; Pectasides M; Farmakis D; Kostopoulou V; Nikolaou M; Gaglia A; Koumpou M; Mylonakis N; Xiros N; Economopoulos T; Raptis SA
    Ann Oncol; 2005 Feb; 16(2):294-9. PubMed ID: 15668287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of docetaxel (Taxotere) in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens.
    Fossella FV; Rigas J
    Semin Oncol; 1999 Jun; 26(3 Suppl 11):9-12. PubMed ID: 10458204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer. A phase II trial conducted by the Groupe Francais de Pneumo-Cancerologie (GFPC).
    Vergnenègre A; Daniel C; Léna H; Fournel P; Kleisbauer JP; Le Caer H; Letreut J; Paillotin D; Pérol M; Bouchaert E; Preux PM; Robinet G;
    Lung Cancer; 2005 Mar; 47(3):395-404. PubMed ID: 15713523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single agents in the second-line treatment of non-small cell lung cancer.
    Belani CP
    Semin Oncol; 1998 Jun; 25(3 Suppl 8):10-4. PubMed ID: 9704670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.